Chief Scientific Officer & Director of Antibody Discovery of Biocytogen
RenMab™ Mouse and InVivo Efficacy-based Solution for Fully Human Antibody Drug Discovery
- January 22, 2020 12:15 pm
Lead and Candidate Selection for Therapeutic Proteins
- Biocytogen has recently developed RenMab™ Mouse, a fully human antibody mouse with its entire variable regions replaced by human Ig heavy chain and light chain. The RenMab™ model has also demonstrated a similar immune response to the wild type strain as it carries the full human antibody repertoire. Combined with existing inventory of single, double or triple target humanized mouse models, Biocytogen is poised to provide an one-stop solution from target validation to IND application.